ACLX

NEUTRALM&A

Arcellx, Inc.

2026-04-01

Price

$114.75

-0.06%

Score5.2Watchlist

Signals6/8 DNA1/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume0.7xvs 20d avg

Analysis

Arcellx's price action is entirely dictated by its pending acquisition by Gilead Sciences for $115 per share in cash plus a $5 Contingent Value Right (CVR). The stock's ultra-low annualized volatility of 2.0% and steady technical signals reflect classic merger arbitrage behavior as the price pins just below the buyout offer. In the current CAUTION (GEOPOLITICAL) macro regime, investors are heavily rewarding this definitive M&A cash deal as a safe-haven asset, absorbing any selling pressure and driving massive relative outperformance against a bearish broader market.

Fired Signals

SURGEALPHA MALESTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUEWEAK FINISH

Key Takeaways

The primary actionable thesis is a merger arbitrage play, with ACLX trading just pennies below Gilead's $115 cash offer, providing a safe haven in a cautious macro environment.
The key risk involves the deal collapsing or facing unexpected delays, though the expiration of the HSR waiting period on March 31 significantly de-risks the transaction.
Watch the April 24, 2026 extended tender offer deadline and monitor the $114.29 support level, which serves as the immediate risk-management floor for arbitrageurs.

← Back to 2026-04-01 View Full ACLX History →Yahoo Finance &nearr;